


Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via First Class Mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
this 9th day of March 2007.

IFW
1614


Jesus Juanos Timoneda, Ph.D.

Docket No. ORT1478USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Breitenbucher et al.

Serial No.: 09/928,122

Art Unit: 1614

Filed: August 10, 2001

Examiner: Ebenezer O. Sackey

For: Substituted Pyrazoles

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

03/13/2007 HLE333 00000022 100750 09928122

01 FC:1806 180.00 DA

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached);
or

☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth in
§1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached);
or

☒ Please charge Deposit Account No. 10-
0750/ORT1478/JJT the fee of \$180.00 as set forth in
§1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

Copies of references that have been made of record in U.S. Application serial number _____, filed _____, are not supplied herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

☐ There are no listed references which are not in the English language.

☒ Concerning references which are not in the English language, the following comments are made: EP 0902027 is in

French, but is the equivalent of US 6,020,336, previously cited for this case. A copy of the front page of US 6,020,336 is provided as an English abstract.

☐ Attached are copies of search report(s) from corresponding patent application(s).

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1478/JJT. This document is being provided in duplicate.


~~Respectfully submitted,~~

Jesús Juanós i Timoneda
Reg. No. 43,332
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(858) 320-3549
DATED: March 9, 2007

Sheet 1 of 1U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ORT1478USNPSERIAL NO.
09/928,122**INFORMATION DISCLOSURE
CITATION BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Breitenbucher et al.FILING DATE
Aug. 10, 2001GROUP ART UNIT
1614**US PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER, INVENTORS, DATE	FILING DATE IF APPROPRIATE
	US 6,287,840 Palmer et al. 09-11-2002	
	US 5,830,850 A Gelb et al. 11-03-1998	
	US 6,214,813 B1 Zhang et al. 04-10-2001	
	US 2002/0040020 Breitenbucher et al. 04-04-2002	
	US 3,994,890 Fujimura et al. 11-30-1976	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER, APPLICANT, DATE	TRANSLATION (IF APPLICABLE)
	EP 0902027 A1 Adir et Compagnie 03-17-1999	Eng abstract
	EP 0747049 A1 Eli Lilly and Company 12-11-1996	

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, etc.
	EBERLEIN-KONIG, et al. Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late-phase cutaneous reactions associated with polle allergen-specific immunotherapy. Clin. Exp. Allergy 1999, 29(12), 1641-1647.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.